Would you want to invest in a biotech with a successful product, surging revenue, and barely any debt? And would your answer change if you heard that the stock's price is less than $7 per share?
Hopefully, your answers are "yes," and "no." For investors eyeing Amarin Corporation (NASDAQ: AMRN) , this isn't an idle exercise. Between the company's hot revenue growth and a deep global market for its newly approved heart disease medication, it has a lot of room to make buyers rich -- as long as generics and competitors don't eat its lunch.
Image source: Getty Images.
For further details see:
Should You Buy Amarin in April?